Asthma Clinical Trial – Now Enrolling
Asthma Clinical Trial – Now Enrolling
The Procare Research Center, is enrolling adults with asthma to evaluate a new investigational medication called solrikitug, which is given as a subcutaneous injection every 4 weeks.
The study aims to determine the drug’s safety, effectiveness, and side effects in people with chronic asthma.
Who can join the RAINIER study?
You may be able to join this study if you meet the
following requirements:​
-
For adults 18–75 years old
-
Must have asthma diagnosed for at least 12 months
-
Must be using 2 or more daily maintenance inhalers
-
Study duration: ~32 weeks
-
Screening (up to 4 weeks)
-
Treatment (12 weeks)
-
Follow-up (16 weeks)
-
-
Participants continue their usual asthma medications
-
Randomized to receive study drug or placebo
-
Participation is voluntary, and you may withdraw at any time
-
To see if this new medication may help improve asthma symptoms and breathing for adults with moderate to severe asthma.
What Will Happen During This Study?
Participation in the RAINIER study lasts about 32 weeks.
Study participants can expect the following:
• Screening Period (up to 4 weeks):
You will review and sign the Informed Consent Form (ICF), which explains the study’s purpose, duration, benefits, risks, tests, and procedures.
You will also have screening and baseline assessments to determine if you meet the requirements to participate.
• Study Treatment Period (12 weeks):
You will attend clinic visits every 4 weeks and receive either the study drug or a placebo (an injection that looks like the study drug but does not contain any active ingredient).
Both are administered as injections under the skin.
• Follow-Up Period (16 weeks):
You will undergo health assessments so that the study doctor and medical staff can monitor your health and observe your body’s response to the study medication.
Throughout the entire study, participants will continue to take their daily maintenance asthma medications as prescribed.
